02137.HK
Brii Biosciences Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.98
+1.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 51.4M | 18.1M | 54.3M | 56.3M | 51.6M |
| Cost of Revenue | 6.8M | — | — | — | — |
| Gross Profit | 44.7M | — | 54.3M | 56.3M | 51.6M |
| Operating Expenses | |||||
| R&D Expense | 426.9M | 206.7M | 249.8M | 402.7M | 440.6M |
| SG&A Expense | 242.6M | 101.7M | 203.9M | 57.1M | 80.3M |
| General & Admin Expense | 132.8M | — | 153.2M | 55.7M | 53.5M |
| Selling & Marketing Expense | 17.8M | — | 50.8M | 1.4M | 26.9M |
| Other Expenses | 8.5M | 1.9M | — | 140.8M | 44.9M |
| Total Operating Expenses | 678.0M | 310.3M | 453.8M | 600.6M | 565.8M |
| Cost and Expenses | 684.8M | 314.0M | 453.8M | 600.6M | 565.8M |
| Operating Income (EBIT) | (628.6M) | (295.9M) | (399.5M) | (544.3M) | (513.8M) |
| Non-Operating | |||||
| Interest Income | 105.2M | 50.2M | 84.8M | 108.0M | 37.2M |
| Interest Expense | 190.2K | 1.9M | — | 494.0K | 851.0K |
| Net Interest Income | 105.0M | 48.3M | 84.8M | 107.5M | 36.4M |
| Other Non-Op Income/Expense | 83.7M | 79.5M | (112.9M) | 359.9M | 24.1M |
| Non-Operating Income (excl Interest) | — | — | — | (360.4M) | — |
| EBT (Pre-Tax Income) | (545.1M) | (216.4M) | (512.4M) | (184.4M) | (489.8M) |
| Income Tax Expense | 1.9M | 1.9M | — | — | (37.2M) |
| Bottom Line | |||||
| Net Income | (543.7M) | (216.9M) | (508.2M) | (174.8M) | (484.3M) |
| Earnings from Cont. Ops | (547.0M) | (218.3M) | (512.4M) | (184.4M) | (489.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (543.7M) | (216.9M) | (508.2M) | (174.8M) | (484.3M) |
| Per Share | |||||
| Basic EPS | (HK$0.75) | (HK$0.30) | (HK$0.70) | (HK$0.24) | (HK$0.67) |
| Diluted EPS | (HK$0.75) | (HK$0.30) | (HK$0.70) | (HK$0.24) | (HK$0.67) |
| Revenue Per Share | HK$0.07 | HK$0.03 | HK$0.07 | HK$0.08 | HK$0.07 |
| Shares | |||||
| Basic Shares Outstanding | 734.4M | 721.9M | 730.2M | 728.1M | 723.5M |
| Diluted Shares Outstanding | 734.4M | 721.9M | 730.2M | 728.1M | 723.5M |
| Profitability Metrics | |||||
| EBITDA | (616.2M) | (290.3M) | (390.7M) | (168.2M) | (496.8M) |
| D&A | 12.4M | 5.6M | 8.8M | 15.7M | 17.0M |
| EBIT | (628.6M) | (295.9M) | (399.5M) | (183.9M) | (513.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026